NIH grants over $500M to create antivirals for future pandemics
As the US transitions away from Covid-19 vaccine science into more therapeutic work, the NIH has awarded $577 million to nine groups in an effort to drive antiviral development for Covid and a slew of other viruses.
The grants will create nine antiviral drug discovery (AViDD) centers, whose main goals are to do the preclinical discovery work for Covid-19 drugs and other viruses “with high potential to cause a pandemic in the future,” according to the NIH press release. The project will span five years, though the initial grant money only extends out to the first three.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 158,600+ biopharma pros reading Endpoints daily — and it's free.